Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling. And now the stock is down over 20% from its 52-week high of $972.53. Could this be a great time to add the high-powered healthcare stock to your portfolio?
Eli Lilly has been a fantastic growth stock to own in recent years. Entering trading this week, its five-year returns have totaled more than 550%. And that means a high valuation may have a lot to do with hesitancy from investors as there may be a lot of concern that the stock has become too expensive — shares of Eli Lilly are trading at a price-to-earnings (P/E) multiple of more than 80.
Even with the stock’s recent drop in value, it is trading at an elevated valuation compared with what it has averaged in recent years.
LLY PE Ratio data by YCharts
Investors may also be concerned that under a new presidential administration, there could be different policies put in place that may impact drug pricing. Last week, the stock closed at $748.01, which is a 7% decline from the $804.73 it closed at on the day of the election, on Nov. 5.
Eli Lilly is a top healthcare company with an extremely promising drug in tirzepatide in its portfolio, which has the potential to best the best-selling drug ever, with analysts estimating that its peak annual sales could top more than $50 billion. The drug has already obtained approval from regulators for diabetes (Mounjaro) and weight loss (Zepbound).
It may also obtain approval to treat sleep apnea in the near future, which would be a game changer for the business, regardless of who is in the White House. The drug is in extremely high demand and could be a growth catalyst for Eli Lilly for years to come.
In the trailing 12 months, Eli Lilly has generated $40.9 billion in revenue and $8.4 billion in profit. It was just a couple of years ago where the business was reporting sales of around $28 billion and showing minimal growth. But now, the company is growing at a much more impressive pace, and it’s still on the cusp of even more amazing growth in the not-too-distant future.
While Eli Lilly’s valuation does look high, over time its continued growth should enable that hefty P/E multiple to come down. And if you believe, as I do, that the stock may potentially top a $1 trillion valuation in the future, there’s good reason to remain bullish on Eli Lilly despite its recent struggles.
Eli Lilly has enormous growth potential, which is why you probably won’t see the stock trading at 20 or 30 times earnings anytime soon. Investors are paying a premium for the business, largely due to tirzepatide and the phenomenal growth potential it possesses.
This is a solid business to invest in, and if you can get it at any kind of discount, it could be a no-brainer worth buying. Eli Lilly is one of the top healthcare stocks you can own for the long haul, and now can be an optimal time to add it to your portfolio.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $355,011!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,516!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $470,586!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of November 25, 2024
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
